COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
Announcing our newest data release for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Lung Squamous Cell Carcinoma (LSCC) Discovery study! Because LSCC accounts for about 30% of all lung cancers and has a ~20% 5-year survival rate, it’s imperative that cancer
In a recent issue of Nature Communications, Clinical Proteomics Tumor Analysis Consortium (CPTAC) researchers from Bing Zhang’s lab at Baylor College of Medicine describe a new bioinformatics software tool developed to evaluate the quality of variant peptide identifications. Using a deep learning algorithm, the software
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce its Virtual Scientific Symposium 2020, September 22nd, 2020. This year’s symposium will feature talks by leaders in the field of proteogenomics and will focus on CPTAC’s tumor characterization and translational studies for pediatric brain cancer, acute myeloid leukemia,
The NCI’s Small Business Innovation Research (SBIR) Development Center has released a program solicitation (PHS 2021-1) which includes a new, Clinical Proteomic Tumor Analysis Consortium (CPTAC)-inspired grant. The announcement calls for the development of hig
This article is the second in the Investigator Spotlight Series that was the brain child of Dr. Dawn Hayward, a NCI Communications Fellow at OCCPR, highlighting our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientists Dr. David Fenyö and researcher Emily Kawaler!
Online on July 24th on Cell Systems, Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers shared the results of their first-ever, crowd-sourced NCI-CPTAC DREAM Proteogenomic Challenge.
A major goal for NCI’s Cancer Proteomic Tumor Analysis Consortium (CPTAC) is to translate proteomic technologies into clinical use to improve treatment and diagnosis of cancer. Dr. Amanda Paulovich and team from the Fred Hutchinson Cancer Research Center (members of the CPTAC Consortium) have achieved an important milestone in this regard, by establishing a Clinical Laboratory Improvement Amendments (CLIA) - certified laboratory for running targeted proteomic assays based on multiple reaction monitoring (MRM) mass spectrometry (MS).
Two new studies released July 9th, 2020 in Cell unravel the biology of lung adenocarcinoma (LUAD) using a suite of molecular techniques that, combined, provide a more complete picture of the disease than ever before.
Join Dr. Alexey Nesvizhskii, Professor of Pathology and Computational Medicine & Bioinformatics at University of Michigan, as he speaks on our next OCCPR Webinar about his ultrafast MSFragger software. The webinar will take place on Wednesday, July 15th at 1pm - registration is free, but required.
The Investigator Spotlight Series was the brain child of Dr. Dawn Hayward, an NCI Communications Fellow at OCCPR, to highlight our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientist Dr. Karin Rodland. Enjoy!
We are so excited to be a part of the AACR Virtual Meeting II, June 22-24, 2020!
In a new study published in Analytical Chemistry, we see another example of ingenuity by NCI’s Office of Cancer Clinical Proteomic Research (OCCPR) Clinical Proteomic Tumor Analysis Consortium (CPTAC) scientists. In an effort to optimize analytical output and conserve hard-to-obtain biospecimen samples, CPTAC researchers out of John Hopkins School of Medicine
108 cases of the NCI’s Clinical Proteomic Tumor Analysis Program (CPTAC) Head and Neck Squamous Cell Carcinoma Discovery Study have been proteomically and genomically profiled! Each case includes HPV-negative, treatment naive and normal adjacent tissue, and includes proteomic ad phosphoproteomic data on the Proteomic Data Commons (PDC), as well as RNA-Seq, miRNA-Seq, WGS, WXS genomic data on the
50 new pathology slides from 33 new Acute Myeloid Leukemia (AML) subjects are now available on the TCIA-CPTAC Pathology Portal. The April 2020 image release brings the total number of AML pathology slides to 120 from 88 subjects, with most of them also having both tumor blood and marrow imaging.
Scientists from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) program developed a powerful tool to explore associations between multiple types of omics datasets. The LinkedOmics software collects genomic, transcriptomic and proteomic datasets from
In a study published on April 21, in Cell Reports Medicine, researchers with the National Cancer Institutes’ (NCI) Clinical Proteomics Tumor Analysis Consortium (CPTAC) take a comprehensive look at the root causes of ovarian high-grade serous carcinoma (HGSC). Through integrated proteomic and genomic an
One of the missions of theClinical Proteomic Tumor Analysis Consortium (CPTAC) is to provide proteomic resources to the greater scientific community. So, we have great news to announce! CPTAC has added 150 "fit-for-purpose," multiplexed, mass spectrometry-based proteomic targeted assays to its Assay Portal!
It’s that time again! CPTAC radiology images have been released on the TCIA CPTAC Pathology Portal! Between conference calls and literature searches, take a look at the 38 new radiology and 8 new pathology images added to Portal – all for free!
Finding novel interactions from comprehensive genomics and proteomics (mass spectrometry generated) is made significantly easier with the help of a visual, interactive guide.
NCI announces the launch of the NCI Proteomic Data Commons (PDC)!